5-årsuppföljning stödjer säkerhet och indikerar positiv behandlingseffekt av Renaparin®

Corline Biomedical AB reported results from a 60-month follow-up of treated patients in RENAPAIR 01 and provided comparisons versus transplanted kidneys. The update is informational but lacks specific outcome metrics (e.g., survival rates, rejection rates, or safety signals) in the provided text.

Analysis

Corline Biomedical AB reported results from a 60-month follow-up of treated patients in RENAPAIR 01 and provided comparisons versus transplanted kidneys. The update is informational but lacks specific outcome metrics (e.g., survival rates, rejection rates, or safety signals) in the provided text.